Glucokinase deficit and birthweight: does maternal hyperglycemia always meet fetal needs?

Abstract

AIMS:

Many authors do not recommend hypoglycemic treatment during pregnancy in women affected by monogenic diabetes due to heterozygous glucokinase (GCK) mutations (MODY 2) in case of affected fetus, because maternal hyperglycemia would be necessary to achieve a normal birthweight. We aimed to evaluate differences in birthweight between MODY 2 affected children according to the parent who carried the mutation.

METHODS:

We retrospectively studied 48 MODY 2 affected children, whose mothers did not receive hypoglycemic treatment during pregnancy, divided into two groups according to the presence of the mutation in the mother (group A) or in the father (group B). Data were extracted from the database of the Regional Centre of Pediatric Diabetology of the University of Campania, Naples, collected from 1996 to 2016. We analyzed birthweight and centile birthweight.

RESULTS:

Percentage of small for gestational age was significantly higher in group B than in group A. We found three large for gestational age in the group that inherited the deficit from the mother, all with the same novel GCK mutation (p.Lys458-Cys461del).

CONCLUSIONS:

We hypothesize that not all MODY 2 affected fetuses need the same levels of hyperglycemia to have an appropriate growth, maybe because different kinds of GCK mutations may result in different phenotypes. Consequently, a "tailored therapy" of maternal hyperglycemia, based on fetal growth frequently monitored through ultrasounds, is essential in MODY 2 pregnancies.

• Authors: Olimpia Bitterman, N Tinto, A Franzese, F Iafusco, C Festa, E Mozzillo, A Napoli, D Iafusco
• Journal: Acta diabetologica (Acta Diabetol) Vol. 55 Issue 12 Pg. 1247-1250 (Dec 2018) ISSN: 1432-5233 [Electronic] Germany
• PMID: 30105470 (Publication Type: Journal Article)

Chemical References

• Hypoglycemic Agents
• Glucokinase

Topics

• Adult
• Birth Weight (genetics)
• Child
• Child, Preschool
• Diabetes Mellitus, Type 2 (blood, drug therapy, genetics)
• Female
• Fetal Development (genetics)
• Fetus (metabolism)
• Gestational Age
• Glucokinase (genetics)
• Humans
• Hyperglycemia (blood, drug therapy, genetics)
• Hypoglycemic Agents (therapeutic use)
• Infant, Newborn
• Male
• Mothers
• Mutation
• Phenotype
• Pregnancy
• Pregnancy in Diabetics (blood, drug therapy, genetics)
• Prenatal Exposure Delayed Effects (blood, genetics, metabolism)
• Retrospective Studies